Clinical Trials · NCT04966741

Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

Name: Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Setmelanotide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Rhythm Pharmaceuticals, Inc.
Enrollment: 12
Start date: Mar 2022
Locations: 6 sites, 4 countries
Primary endpoint: Percentage of Participants With Greater Than or Equal to (≥) 0.2 Reduction of BMI Z-Score From Baseline to Week 52

View Setmelanotide compound reference